NARMAFOTINIB Large-Scale Manufactre Complete

Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing environment - a key step in Phase-3 readiness Sufficient drug supply to support Amplia’s pancreatic cancer trials and other planned studies, supporting the Company's clinical development pipeline Melbourne, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF ...